Awareness Days Head and Neck Tumors
From September 20 to 24, 2021
Status: 17.09.2021
It is estimated that around 50 out of every 100,000 people in Germany develop head and neck cancer every year. The pharynx, oral cavity and larynx are most frequently affected. Due to the unspecific symptoms, many patients often go to the physician late. As a result, the tumor is then often at an advanced stage.
In order to raise awareness of head and neck tumors in the population and improve the chances of recovery through education and early detection, the CCC Hannover and the Head and Neck Tumor Center are taking part in the " Make Sense" campaign week of the European Head and Neck Society (EHNS).
Inquired
...from our experts at the Head and Neck Tumor Center
Head and neck tumors - Which areas of the head and neck are covered?
"Head and neck tumors include a whole range of different tumors, especially of the oral cavity, jaw, tongue, but also of the larynx and salivary glands."
Prof. Dr. Dr. med. Frank Tavassol, Deputy Clinical Director and Senior Consultant Tumor Surgery at the Clinical Department of Oral and Maxillofacial Surgery
What are risk factors for the development of head and neck tumors?
"Risk factors for the development of head and neck tumors are usually the consumption of high-proof alcohol and smoking. But other factors, such as genetic aspects or viral infections, can also contribute to the development of a head and neck tumor."
Prof. Dr. med. Frank Tavassol, Deputy Clinical Director and Senior Consultant Tumor Surgery at the Clinical Department of Oral and Maxillofacial Surgery
What signs indicate tumors in the head or throat and when should you see a physician?
"Hoarseness for more than three weeks is the leading sign of laryngeal cancer. It can either be ruled out or the suspicion confirmed during an ENT mirror examination by the ENT physician. Head and neck malignancies have very diverse and very unspecific symptoms. These include symptoms such as throat swelling, difficulty swallowing, unspecific unilateral nasal secretions or bloody, mucous secretions from the nose, tympanic effusion or restricted mobility of the lower jaw. As you can see, very unspecific. What is striking is the fact that patients usually present to ENT colleagues in private practice with a T2 stage or higher, which means that the tumor is at least 2 centimetres in size. This has a negative impact on subsequent treatment. That's why it makes a lot of sense for patients to see their ENT specialists for regular check-ups and simply have themselves checked."
PD Dr. med. Martin Durisin, Center Coordinator Head and Neck Tumor Center and Senior Consultant Tumor Surgeon at the Clinical Department of Ear, Nose and Throat Medicine
What treatment options are available?
"Various treatment concepts are available. Surgery, radiotherapy, drug therapy and, more recently, immunotherapy. The therapy concept for each individual patient is specifically and individually tailored to the patient and their disease in a tumor conference with experts from various tumor disciplines. Small tumors can be treated surgically. In the case of large tumors, we usually speak of multimodal therapy concepts, which means that several specialist disciplines are involved in the treatment with the aim of curing the patient."
PD Dr. med. Martin Durisin, Center Coordinator Head and Neck Tumor Center and Senior Consultant Tumor Surgeon at the Clinical Department of Ear, Nose and Throat Medicine
What are the consequences of the therapies for the patient? How "gentle" are they?
"In recent decades, therapies in surgery, radiotherapy, drug therapy and immunotherapy have developed considerably. In surgery, we have at our disposal: intraoperative navigation, intraoperative imaging, CO2 laser, robot-assisted surgery. Radiotherapy has undergone enormous technical development. Nowadays it is gentle on the tissue and very tumor-specific. New tumor-specific drugs have been introduced in drug therapy. In addition, immunotherapy has been admitted for the treatment of head and neck squamous cell carcinoma in recent years. All these innovations in therapies mean that treatment is now more precise and specific. This is of course also reflected in the success of the therapy and the survival rate increases. The aim of the therapy is to maintain functionality and, of course, the cosmetics and healing of the patient. In the case of laryngeal carcinoma, we are talking about an organ that is responsible for a very complex function, namely "speech". Today's treatment concepts make it possible to preserve the voice in the vast majority of cases."
PD Dr. med. Martin Durisin, Center Coordinator Head and Neck Tumor Center and Senior Consultant Tumor Surgeon at the Clinical Department of Ear, Nose and Throat Medicine
Laryngeal cancer: What happens after treatment and what does aftercare look like?
"After the treatment of a patient with a carcinoma of the larynx, the first step is rehabilitation. The focus here is on the voice but also on the act of swallowing. This rehabilitation is carried out by colleagues and cooperation partners. These are, on the one hand, voice therapists and, on the other hand, cooperation clinics that specialize in the rehabilitation of patients after cancer treatment, especially for swallowing training. Once treatment and rehabilitation measures have been completed, the patient remains in tumor aftercare for 10 years to rule out tumor recurrence."
PD Dr. med. Martin Durisin, Center Coordinator Head and Neck Tumor Center and Senior Consultant Tumor Surgeon at the Clinical Department of Ear, Nose and Throat Medicine
Why can it be useful to take part in clinical trials?
"Actually, all expert committees recommend that a patient should always be treated in a trial if possible. Why? The quality of the treatment is usually outstanding, because a committee of experts has given the treatment a lot of thought beforehand. The second aspect is that, despite all the innovations, we patients are not satisfied with the options we have and always want more options. A study can certainly be an opportunity to participate in the therapy of the future today."
PD Dr. Philipp Ivanyi, Senior Physician at the Clinical Department of Haematology, Haemostaseology, Oncology and Stem Cell Transplantation
On the topic:
Kick-off meeting | Strengthening self-help KHT in the Hanover region
Friday, September 24, 2021, 12 p.m. - 1 p.m., online meeting
The diagnosis of cancer often hits those affected and their relatives like a bolt from the blue. Self-help groups provide an important point of contact with their counseling and support services after the diagnosis, but also after the hospital stay. Discussions with people who are affected in the same way offer the opportunity to talk about the new life situation and to learn from the experience of others who are ill.
In order to strengthen the self-help network in the Hannover region, a kick-off meeting to establish another self-help group will take place on Friday, September 24, 2021.
The participants and contact persons of the Oncology Center of the CCC Hannover, the Head and Neck Tumor Center, the self-help network Kopf-Hals-M.U.N.D.-Krebs e.V., the self-help group Kehlkopflose und Kehlkopfoperierte Hannover im Landesverband Niedersachsen e.V. and affected patients will meet. Experiences are to be exchanged and initial ideas developed in a closed circle.
Closed event. No registration possible for external participants.
About the Awareness Week
The Awareness Week of the European Head and Neck Society (EHNS) and the Interdisciplinary Working Group Head and Neck Tumors of the DKG (IAG-KHT) for head and neck cancer is taking place for the ninth time this year. The Europe-wide "Make Sense" campaign was launched by the European Head and Neck Society (EHNS) in cooperation with the national organizations. The aim of the campaign is to raise awareness of the disease and its symptoms in order to improve the chances of a cure through education and early detection.
Further information:
European Head and Neck Society (EHNS)Further information about the 9th Head and Neck Tumor Action Week
Head and Neck Tumor Center
Contact persons and consultation hours
Clinical Department of Ear, Nose and Throat MedicineDirector of the Clinical Department Prof. Prof. h.c. Dr. med. Th. Lenarz
Director of the Clinical Department Univ.-Prof. Dr. Dr. Nils-Claudius Gellrich
Self-help group "Laryngectomees and laryngectomized persons - Self-help group in the Lower Saxony regional association" Head and Neck M.U.N.D. Cancer Self-Help Network e.V.